Plain-English translation of NCT05201404 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new drug called to see if it can help treat advanced liver cancer in people who have a particular type of severe cirrhosis (scarring of the liver) and whose cancer has already progressed despite at least one prior treatment. About two-thirds of participants will receive the medication, while the remaining third will receive a placebo (inactive pill), and neither participants nor researchers will know which is which until the study ends. The study will follow participants for as long as the medication is helping and appears safe.
Advanced liver cancer that doesn't respond to standard treatments is very serious, and patients with severe cirrhosis have limited options. This medication is being tested because early research suggests it may help slow or stop cancer growth in this difficult-to-treat population.
You likely qualify if…
You likely don't qualify if…
If you join, you will take either the new medication or a placebo by mouth twice daily in 28-day cycles. You'll have regular safety check-ups and imaging scans every two cycles to see how the cancer is responding. You'll continue treatment as long as the cancer is not growing and you're tolerating the medication well, with follow-up visits for at least 28 days after you stop taking the study drug. If you consent, researchers will also check on your survival status over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Bosnia and Herzegovina
Bulgaria